Two years af­ter a ‘pos­i­tive’ re­sult tanked their stock, Ovid's Je­re­my Levin wins a part­ner for the PhI­II jour­ney

If Je­re­my Levin could do it over again, he says he would.

Two years ago, his com­pa­ny, Ovid Ther­a­peu­tics, re­leased the topline da­ta from a Phase II tri­al on their lead drug, for a rare neu­ro­log­i­cal con­di­tion called An­gel­man syn­drome. Ovid called it “pos­i­tive,” point­ing to one sec­ondary end­point called CGI-I. An­a­lysts and in­vestors saw the 16 oth­er end­points that weren’t pos­i­tive, called the one suc­cess a fluke, and the stock fell 80%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER